PL2129693T3 - Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae - Google Patents

Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae

Info

Publication number
PL2129693T3
PL2129693T3 PL08732592T PL08732592T PL2129693T3 PL 2129693 T3 PL2129693 T3 PL 2129693T3 PL 08732592 T PL08732592 T PL 08732592T PL 08732592 T PL08732592 T PL 08732592T PL 2129693 T3 PL2129693 T3 PL 2129693T3
Authority
PL
Poland
Prior art keywords
production
purification process
streptococcus pneumoniae
pneumoniae polysaccharides
shortened purification
Prior art date
Application number
PL08732592T
Other languages
English (en)
Inventor
Yonghui Yuan
Mark Ruppen
Wei-Qiang Sun
Ling Chu
John Simpson
James Patch
Charbonneau Pamela Fink
Justin K. Moran
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39712482&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2129693(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PL2129693T3 publication Critical patent/PL2129693T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • C07H1/08Separation; Purification from natural products
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/04Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087Polysaccharides; Lipopolysaccharides [LPS]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Sustainable Development (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL08732592T 2007-03-23 2008-03-20 Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae PL2129693T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89661607P 2007-03-23 2007-03-23
EP08732592.4A EP2129693B1 (en) 2007-03-23 2008-03-20 Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides

Publications (1)

Publication Number Publication Date
PL2129693T3 true PL2129693T3 (pl) 2017-07-31

Family

ID=39712482

Family Applications (3)

Application Number Title Priority Date Filing Date
PL08732592T PL2129693T3 (pl) 2007-03-23 2008-03-20 Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae
PL18177128.8T PL3406635T3 (pl) 2007-03-23 2008-03-20 Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae
PL11194173T PL2436700T3 (pl) 2007-03-23 2008-03-20 Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL18177128.8T PL3406635T3 (pl) 2007-03-23 2008-03-20 Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae
PL11194173T PL2436700T3 (pl) 2007-03-23 2008-03-20 Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae

Country Status (30)

Country Link
US (3) US8652480B2 (pl)
EP (3) EP2129693B1 (pl)
JP (5) JP5688902B2 (pl)
KR (2) KR101500771B1 (pl)
CN (1) CN101663327B (pl)
AU (1) AU2008231041B2 (pl)
BR (1) BRPI0809212B8 (pl)
CA (1) CA2681570C (pl)
CL (2) CL2008000831A1 (pl)
CO (1) CO6251324A2 (pl)
CR (1) CR11041A (pl)
DK (3) DK2436700T5 (pl)
EC (1) ECSP099652A (pl)
ES (3) ES2922132T3 (pl)
GT (1) GT200900249A (pl)
HK (1) HK1141815A1 (pl)
HN (1) HN2009001965A (pl)
HU (3) HUE059085T2 (pl)
IL (1) IL201106A (pl)
MX (1) MX2009010221A (pl)
MY (1) MY150927A (pl)
NI (1) NI200900172A (pl)
NZ (1) NZ580134A (pl)
PL (3) PL2129693T3 (pl)
PT (3) PT2129693T (pl)
RU (1) RU2516340C2 (pl)
SI (3) SI2436700T1 (pl)
UA (1) UA99278C2 (pl)
WO (1) WO2008118752A2 (pl)
ZA (1) ZA200906625B (pl)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2129693T3 (pl) * 2007-03-23 2017-07-31 Wyeth Llc Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae
GB0818453D0 (en) * 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PT2349520T (pt) * 2008-10-27 2016-08-16 Glaxosmithkline Biologicals Sa Método de purificação para hidrato de carbono de estreptococos grupo a
PT2385981T (pt) * 2008-12-18 2019-10-28 Wyeth Llc Método para controlar peso molecular de polissacárido de streptococcus pneumoniae com a utilização de carbono.
US8795689B2 (en) * 2008-12-18 2014-08-05 Wyeth Llc Method for controlling Streptococcus pneumoniae serotype 19A polysaccharide molecular weight
BRPI1014494A2 (pt) 2009-04-30 2016-08-02 Coley Pharm Group Inc vacina pneumocócica e usos da mesma
US9125951B2 (en) 2009-06-22 2015-09-08 Wyeth Llc Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SI2445522T1 (sl) 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
US8841104B2 (en) 2010-04-21 2014-09-23 Nanomr, Inc. Methods for isolating a target analyte from a heterogeneous sample
US20110262989A1 (en) 2010-04-21 2011-10-27 Nanomr, Inc. Isolating a target analyte from a body fluid
US9476812B2 (en) 2010-04-21 2016-10-25 Dna Electronics, Inc. Methods for isolating a target analyte from a heterogeneous sample
WO2011145108A2 (en) * 2010-05-15 2011-11-24 Serum Institute Of India Ltd. Purification of capsular polysaccharides
WO2012127485A1 (en) * 2011-03-22 2012-09-27 Serum Institute Of India Ltd. A novel process for preparation of polysaccharides
CN102660601B (zh) * 2012-04-17 2015-10-28 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
CN102660602B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 快速纯化细菌荚膜多糖的方法
CN102660603B (zh) * 2012-04-17 2015-03-25 江苏康泰生物医学技术有限公司 一种快速纯化细菌荚膜多糖的方法
US9650411B2 (en) * 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
EP2894225B1 (en) * 2012-09-07 2017-11-22 SK Chemicals Co., Ltd. Production method for capsular polysaccharide having pneumococcal serotype
CA2896552A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic compositions
US9434940B2 (en) 2012-12-19 2016-09-06 Dna Electronics, Inc. Methods for universal target capture
US9804069B2 (en) 2012-12-19 2017-10-31 Dnae Group Holdings Limited Methods for degrading nucleic acid
US10000557B2 (en) 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
US9995742B2 (en) 2012-12-19 2018-06-12 Dnae Group Holdings Limited Sample entry
US9551704B2 (en) 2012-12-19 2017-01-24 Dna Electronics, Inc. Target detection
US9599610B2 (en) 2012-12-19 2017-03-21 Dnae Group Holdings Limited Target capture system
EP3019521A1 (en) 2013-07-12 2016-05-18 EMD Millipore Corporation A method of determining virus removal from a sample containing a target protein using activated carbon
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
JP6612260B2 (ja) 2014-01-21 2019-11-27 ファイザー・インク 肺炎連鎖球菌(Streptococcus pneumoniae)莢膜多糖およびそのコンジュゲート
EP3616716A3 (en) 2014-01-21 2020-05-06 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
SI3096786T1 (sl) 2014-01-21 2021-09-30 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CN107427568B (zh) 2015-01-15 2021-12-14 辉瑞公司 用于肺炎球菌疫苗中的免疫原性组合物
EP3292146A1 (en) 2015-05-04 2018-03-14 Pfizer Inc Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
EP3312287A4 (en) * 2015-06-18 2018-12-19 The Research Foundation for Microbial Diseases of Osaka University Method for measuring complement-dependent bactericidal function with respect to pneumococci
PE20240927A1 (es) 2015-07-21 2024-04-30 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos
CN105131139B (zh) * 2015-07-31 2018-02-13 兰州生物制品研究所有限责任公司 一种肺炎链球菌荚膜多糖的纯化方法
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
IL264553B2 (en) 2016-08-05 2023-04-01 Sanofi Pasteur Inc A multivalent pneumococcal protein-polysaccharide conjugate preparation
TWI789357B (zh) 2016-08-05 2023-01-11 南韓商Sk生物科技股份有限公司 多價肺炎球菌多醣-蛋白質共軛物組成物(二)
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
CA3048981A1 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
ES2911490T3 (es) 2017-01-20 2022-05-19 Pfizer Composiciones inmunogénicas para su uso en vacunas antineumocócicas
CN110225757A (zh) 2017-01-31 2019-09-10 默沙东公司 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
CN110337307A (zh) 2017-02-24 2019-10-15 默沙东公司 增强肺炎链球菌多糖-蛋白缀合物的免疫原性
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
KR102634811B1 (ko) 2017-06-10 2024-02-06 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US10435433B2 (en) 2017-07-05 2019-10-08 Inventprise, Llc Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography
US10702596B2 (en) 2017-07-05 2020-07-07 Inventprise, Llc Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography
CA3074703A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
JP7218358B2 (ja) 2017-09-07 2023-02-06 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖体および免疫原性多糖体-キャリアタンパク質コンジュゲートでのその使用
CN118063638A (zh) 2017-09-07 2024-05-24 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
CN107936128B (zh) * 2017-11-22 2020-07-03 成都欧林生物科技股份有限公司 一种简便有效的细菌疫苗纯化方法
JP7369123B2 (ja) 2017-12-06 2023-10-25 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌多糖類-タンパク質コンジュゲートを含む組成物およびその使用方法
KR20210005158A (ko) 2018-04-30 2021-01-13 머크 샤프 앤드 돔 코포레이션 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 담체 단백질 접합체를 제조하는 방법
KR20210002641A (ko) 2018-04-30 2021-01-08 머크 샤프 앤드 돔 코포레이션 디메틸술폭시드 중의 동결건조된 돌연변이체 디프테리아 독소의 균질 용액을 제공하는 방법
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
CN112543649A (zh) 2018-07-04 2021-03-23 Vaxcyte公司 免疫原性缀合物的改进
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
CN112673054A (zh) * 2018-07-19 2021-04-16 葛兰素史密丝克莱恩生物有限公司 用于制备干燥多糖的方法
JP2022512345A (ja) 2018-12-12 2022-02-03 ファイザー・インク 免疫原性多重ヘテロ抗原多糖-タンパク質コンジュゲートおよびその使用
MA54533A (fr) 2018-12-19 2022-03-30 Merck Sharp & Dohme Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation
JP7239509B6 (ja) * 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
AU2020323498A1 (en) 2019-07-31 2022-03-03 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
US20210070890A1 (en) * 2019-09-06 2021-03-11 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
JP2021132644A (ja) * 2020-02-21 2021-09-13 ファイザー・インク 糖の精製
CA3192786A1 (en) 2020-08-26 2022-03-03 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
GB202016165D0 (en) 2020-10-12 2020-11-25 Optivalent Ltd Vaccine
CA3199094A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
AU2021373358A1 (en) 2020-11-04 2023-06-01 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
JP2024517780A (ja) 2021-05-03 2024-04-23 ファイザー・インク 細菌およびベータコロナウイルス感染症に対するワクチン接種
MX2023013434A (es) 2021-05-28 2023-12-12 Pfizer Inc Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
GB2614916A (en) 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002004B1 (en) 1977-11-07 1982-03-24 Ciba-Geigy Ag Process for the manufacture of fluorinated cationic compounds and their use as surfactants
CA1115210A (en) * 1977-11-28 1981-12-29 Dennis J. Carlo Pneumococcal vaccine
US4221906A (en) * 1979-03-19 1980-09-09 American Cyanamid Company Stabilization of pneumococcal polysaccharides
US4242501A (en) * 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
FR2495939B1 (fr) * 1980-12-11 1985-10-11 Merieux Inst Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
JPS6170994A (ja) * 1984-09-14 1986-04-11 Daikin Ind Ltd 環状(1→2)−β−D−グルカンの製法
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5714354A (en) * 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
RU2087156C1 (ru) * 1995-06-22 1997-08-20 Леонид Николаевич Падюков Вакцина против пневмококковой инфекции
KR100757630B1 (ko) * 1997-12-23 2007-09-10 박스터 헬쓰케어 에스.에이. 신규한 추출 및 단리 방법으로 수득되는 세균성 캡슐형 다당류
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
GB0108079D0 (en) * 2001-03-30 2001-05-23 Microbial Technics Ltd Protein
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN102716480B (zh) * 2005-04-08 2023-03-21 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
NZ562719A (en) * 2005-04-08 2008-12-24 Wyeth Corp Separation of contaminants from streptococcus pneumoniae polysaccharide by pH manipulation
PL2129693T3 (pl) * 2007-03-23 2017-07-31 Wyeth Llc Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae

Also Published As

Publication number Publication date
MY150927A (en) 2014-03-14
BRPI0809212B1 (pt) 2019-06-18
EP3406635B1 (en) 2022-05-11
ES2922132T3 (es) 2022-09-08
DK2436700T5 (en) 2018-09-03
EP2436700B8 (en) 2018-08-01
RU2009135485A (ru) 2011-04-27
CA2681570C (en) 2016-05-03
JP6825950B2 (ja) 2021-02-03
US8652480B2 (en) 2014-02-18
KR101500771B1 (ko) 2015-03-18
CO6251324A2 (es) 2011-02-21
HN2009001965A (es) 2011-10-06
ECSP099652A (es) 2009-10-30
JP2019048844A (ja) 2019-03-28
AU2008231041B2 (en) 2013-03-07
CN101663327B (zh) 2014-05-07
WO2008118752A3 (en) 2008-11-20
JP5688902B2 (ja) 2015-03-25
IL201106A (en) 2014-04-30
IL201106A0 (en) 2010-05-17
CN101663327A (zh) 2010-03-03
RU2516340C2 (ru) 2014-05-20
PT3406635T (pt) 2022-07-08
SI3406635T1 (sl) 2022-08-31
HUE059085T2 (hu) 2022-10-28
JP2010521972A (ja) 2010-07-01
CL2008000831A1 (es) 2008-07-04
PL2436700T3 (pl) 2018-12-31
HUE031567T2 (hu) 2017-07-28
BRPI0809212A2 (pt) 2014-09-02
SI2436700T1 (sl) 2018-09-28
US20150165017A1 (en) 2015-06-18
DK2436700T3 (en) 2018-08-13
CR11041A (es) 2009-12-30
EP3406635A1 (en) 2018-11-28
DK3406635T3 (da) 2022-05-30
ES2677353T3 (es) 2018-08-01
JP6872649B2 (ja) 2021-05-19
PT2129693T (pt) 2017-02-14
HK1141815A1 (en) 2010-11-19
ES2677353T8 (es) 2018-09-25
ZA200906625B (en) 2010-07-28
JP2020169160A (ja) 2020-10-15
EP2129693B1 (en) 2016-12-07
US9675681B2 (en) 2017-06-13
JP2015143225A (ja) 2015-08-06
PT2436700T (pt) 2018-07-17
CL2017002029A1 (es) 2018-05-18
US8999697B2 (en) 2015-04-07
SI2129693T1 (sl) 2017-01-31
EP2436700A1 (en) 2012-04-04
CA2681570A1 (en) 2008-10-02
ES2614249T3 (es) 2017-05-30
UA99278C2 (ru) 2012-08-10
EP2129693A2 (en) 2009-12-09
MX2009010221A (es) 2009-10-19
JP2017141263A (ja) 2017-08-17
WO2008118752A2 (en) 2008-10-02
NI200900172A (es) 2010-09-07
KR20100015765A (ko) 2010-02-12
PL3406635T3 (pl) 2022-08-22
US20140363463A1 (en) 2014-12-11
AU2008231041A8 (en) 2009-11-12
EP2436700B1 (en) 2018-06-20
GT200900249A (es) 2010-07-28
US20080286838A1 (en) 2008-11-20
NZ580134A (en) 2011-10-28
KR20150021127A (ko) 2015-02-27
HUE039169T2 (hu) 2018-12-28
AU2008231041A1 (en) 2008-10-02
BRPI0809212B8 (pt) 2021-05-25
DK2129693T3 (en) 2017-02-13

Similar Documents

Publication Publication Date Title
IL201106A0 (en) Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides
EP1999134A4 (en) PROCESS FOR PREPARING ANYHYDRUGAL ALCOHOLS
EG25753A (en) Process for the production of alcohols
EP2170919A4 (en) IMPROVED PROCESS FOR THE PRODUCTION OF NUCLEOTIDE SUGARS
EP2189435A4 (en) PROCESS FOR PREPARING A PROPYLENE
IL220430A0 (en) Process for the production of benzopyran-2-ol derivatives
GB0920383D0 (en) Process for the production of sucrose-6-ester
HK1160097A1 (en) Process for the production of ammonia
IL202153A0 (en) Process for the production of pyrazoles
GB0807808D0 (en) Process for the production of oligosaccharides
IL227837A0 (en) A process for purifying theobromine
IL185722A0 (en) Process for the production of methylcobalamin
ZA201000237B (en) Process for the production of tertiary alcohols
EP2221294A4 (en) PROCESS FOR PREPARING N-CARBAMOYL-TERT.-LEUCIN
EP1975146A4 (en) PROCESS FOR PRODUCING 1,6-HEXANEDIOL
EP2108036A4 (en) PROCESS FOR PRODUCING ALCANOLAMINE
PL2194796T3 (pl) Sposób wytwarzania czekolady
EP2221290A4 (en) PROCESS FOR THE PREPARATION OF ALKOXYINDANONE DERIVATIVES
GB0718398D0 (en) Process for the production of alcohols
EP2077259A4 (en) PROCESS FOR THE PRODUCTION OF 2,6-DIMETHYL-1-NAPHTHALDEHYDE
HUP0700244A2 (en) Process for the production of alcohol
SI2029567T1 (sl) Postopek za proizvodnjo derivator benzopiran-2-ola
PL381675A1 (pl) Sposób wytwarzania wyrobów porcelanowych
ZA201002012B (en) Catalyst production process